For U.S. users: The VLVbio K18 assays have not been approved by the U.S. Food and Drug Administration

M30 Apoptosense® ELISA

Product no. 10011

The M30 Apoptosense® ELISA measures the amount of caspase cleaved keratin 18 in human serum and cell culture supernatants, as well as cell spheroids and xenograft models, reflecting the amount of apoptosis. The assays are based on the unique M30® antibody, which recognizes a neo-epitope of keratin 18 formed after caspase cleavage.

The M30 Apoptosense® ELISA is CE marked as a medical device for in vitro diagnostic use. All reagents are provided in a convenient ready-to-use format. The product is not cleared by the FDA for clinical use in the US.

M30 APOPTOSENSE® ELISA M30 APOPTOSENSE® ELISA M30 APOPTOSENSE® ELISA M30 APOPTOSENSE® ELISA M30 APOPTOSENSE® ELISA 

Product characteristics

The test has 96 determinations: 7 standards, 2 controls and 39 test samples in duplicate.

The test has 96 determinations: 7 standards, 2 controls and 39 test samples in duplicate.

Assay procedure takes approximately 5 hours.

Sample type: human serum. Multiple freeze-thaw cycles of samples are well tolerated.

Reagent storage: +2 – 8 °C.

Can be split up for use at several occasions.

Assay Procedure

Assay Procedure of M30 Apoptosense® ELISA

Clinical IVD application for the M30 Apoptosense® ELISA:

Clinical IVD application

In Non-Alcoholic Fatty Liver Disease

As an aid in diagnosing Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Liver Disease suspect patients.

The test has 96 determinations: 7 standards, 2 controls and 39 test samples in duplicate.

As an intervention follow-up to check for treatment effect in NASH patients.

In Alcoholic Liver Disease

As an aid in diagnosing Alcoholic Steatohepatitis (ASH) in Alcoholic Liver Disease (ALD) suspect patients.

As a prognostic tool and treatment response prediction in ASH patients.

Research Fields

Hepatology

The M30 Apoptosense® ELISA measures the amount hepatocyte apoptosis in patients with liver diseases and is used to diagnose and screen for liver diseases such as Non-alcoholic Steatohepatitis, Alcoholic Steatohepatitis and Hepatitis B.

Oncology

The M30 Apoptosense® ELISA can specifically detect compounds that induce apoptosis, a major goal of anti-cancer drugs, as well as monitor the efficacy of therapy during the course of treatment.

Toxicology

Many pharmaceutical agents and substances are known to be hepatotoxic when administered in high doses, a common reason for patient hospitalization and withdrawal of approved drugs from the market. The M30 Apoptosense® ELISA can be used to detect elevated levels of ccK18 as a result of hepatotoxicity due to e.g. Drug-Induced Liver Injury or Toxicant-Associated Steatohepatitis.

Together with other products

The assay can be combined with the M65® ELISA for further analysis of the cell death mode (necrosis or apoptosis). As both assays are calibrated against the identical reference, the combination of the M30 Apoptosense® ELISA and the M65® ELISA allows determination of the relative contribution of apoptosis to total cell death.

Order the M30 Apoptosense® ELISA from your local distributor